Related Experiment Video
Updated: Jun 12, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Aberrant pre-mRNA processing in cancer
Jeetayu Biswas1,2, Leora Boussi2, Eytan Stein2
1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Dysregulation of the flow of information from genomic DNA to RNA to protein occurs within all cancer types. In this review, we described the current state of understanding of how RNA processing is dysregulated in cancer with a focus on mutations in the RNA splicing factor machinery that are highly prevalent in hematologic malignancies. We discuss the downstream effects of these mutations highlighting both individual genes as well as common pathways that they perturb. We highlight examples of how alterations in RNA processing have been harnessed for therapeutic intent as well as to promote the selective toxicity of cancer cells.
Insights
Cancer involves errors in RNA processing, particularly splicing factor mutations common in blood cancers. Understanding these changes offers new therapeutic strategies for selective cancer cell toxicity.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Gene expression relies on accurate information flow from DNA to RNA to protein.
- Dysregulation of this process is a hallmark of all cancer types.
- RNA processing, especially splicing, is frequently altered in malignancies.
Purpose of the Study:
- To review the current understanding of RNA processing dysregulation in cancer.
- To focus on mutations in RNA splicing machinery prevalent in hematologic malignancies.
- To explore therapeutic strategies targeting RNA processing alterations.
Main Methods:
- Literature review of current research on RNA processing in cancer.
- Analysis of mutations in RNA splicing factors.
- Examination of downstream effects and affected pathways.
- Identification of therapeutic applications and selective toxicity mechanisms.
Main Results:
- Mutations in RNA splicing factors are highly prevalent in hematologic malignancies.
- These mutations lead to dysregulated RNA processing with significant downstream effects.
- Specific genes and common pathways are perturbed by these splicing factor mutations.
- Alterations in RNA processing can be exploited for therapeutic benefit.
Conclusions:
- Dysregulated RNA processing, particularly via splicing factor mutations, is critical in cancer development.
- Targeting these RNA processing defects presents promising therapeutic avenues for hematologic malignancies.
- Understanding these mechanisms enhances strategies for selective cancer cell killing.
Related Concept Videos
RNA Splicing
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Nuclear Export of mRNA
Pre-mRNA Processing: Modification of pre-mRNA Ends
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...

